WO2013111013A8 - Methods for treating alzheimer's disease by administering certain synthetic compounds - Google Patents

Methods for treating alzheimer's disease by administering certain synthetic compounds Download PDF

Info

Publication number
WO2013111013A8
WO2013111013A8 PCT/IB2013/000458 IB2013000458W WO2013111013A8 WO 2013111013 A8 WO2013111013 A8 WO 2013111013A8 IB 2013000458 W IB2013000458 W IB 2013000458W WO 2013111013 A8 WO2013111013 A8 WO 2013111013A8
Authority
WO
WIPO (PCT)
Prior art keywords
disease
methods
treating alzheimer
synthetic compounds
certain synthetic
Prior art date
Application number
PCT/IB2013/000458
Other languages
French (fr)
Other versions
WO2013111013A3 (en
WO2013111013A2 (en
Inventor
Weiwei Ma
Original Assignee
Beijing Joekai Biotechnology Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/022646 external-priority patent/WO2012103282A2/en
Application filed by Beijing Joekai Biotechnology Llc filed Critical Beijing Joekai Biotechnology Llc
Priority to CN201380006684.XA priority Critical patent/CN104411308B/en
Priority to US14/374,573 priority patent/US9084793B2/en
Publication of WO2013111013A2 publication Critical patent/WO2013111013A2/en
Publication of WO2013111013A3 publication Critical patent/WO2013111013A3/en
Publication of WO2013111013A8 publication Critical patent/WO2013111013A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Use of a synthetic compound selected from the group consisting of JKF-006, JKF-011 and JKF-027 in the preparation of a medicament for treating Alzheimer's disease.
PCT/IB2013/000458 2011-01-26 2013-01-25 Methods for treating alzheimer's disease by administering certain synthetic compounds WO2013111013A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201380006684.XA CN104411308B (en) 2012-01-26 2013-01-25 By the method giving some synthesis compounds for treating Alzheimer
US14/374,573 US9084793B2 (en) 2011-01-26 2013-01-25 Methods for treating Alzheimer's disease by administering certain synthetic compounds

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2012/022646 WO2012103282A2 (en) 2011-01-26 2012-01-26 Methods and compositions for treating alzheimer's disease
USPCT/US2012/022646 2012-01-26
USPCT/US2012/0022646 2012-01-26

Publications (3)

Publication Number Publication Date
WO2013111013A2 WO2013111013A2 (en) 2013-08-01
WO2013111013A3 WO2013111013A3 (en) 2013-10-31
WO2013111013A8 true WO2013111013A8 (en) 2014-08-07

Family

ID=48874665

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/000458 WO2013111013A2 (en) 2011-01-26 2013-01-25 Methods for treating alzheimer's disease by administering certain synthetic compounds

Country Status (2)

Country Link
CN (1) CN104411308B (en)
WO (1) WO2013111013A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201809295D0 (en) 2018-06-06 2018-07-25 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
GB201818750D0 (en) 2018-11-16 2019-01-02 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101273962A (en) * 2007-11-22 2008-10-01 山东蓝金生物工程有限公司 Temperature controlled sustained-release injection comprising alkyl agent and method for preparing the same
WO2012103282A2 (en) * 2011-01-26 2012-08-02 Zhong Yi Methods and compositions for treating alzheimer's disease

Also Published As

Publication number Publication date
CN104411308A (en) 2015-03-11
WO2013111013A3 (en) 2013-10-31
WO2013111013A2 (en) 2013-08-01
CN104411308B (en) 2016-09-28

Similar Documents

Publication Publication Date Title
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2012062925A3 (en) Compounds and methods for treating pain
WO2013170068A3 (en) Nuclear transport modulators and uses thereof
ZA201405101B (en) "new indolizine compounds, a process for their preparation and pharmaceutical compositions containing them."
WO2012118812A3 (en) Substituted 6,5-fused bicyclic heteroaryl compounds
PH12015501993A1 (en) Pyrazole-amide compound and medicinal uses therefor
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
MX364229B (en) COMPOSITIONS and METHODS FOR TREATING CARDIOVASCULAR DISEASES.
EA026667B9 (en) Pharmaceutical composition for treating hepatitis c virus
WO2013057570A3 (en) Acrylic polymer formulations
PL2739615T3 (en) Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament
IL232764A (en) Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines, pharmaceutical compositions comprising them and use thereof in the manufacture of medicaments for the treatment of alzheimer's disease
ZA201401678B (en) Novel distributed 3,4-diamino-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases
WO2013003669A3 (en) Compositions, methods of use, and methods of treatment
WO2013040227A3 (en) Therapeutic compounds
WO2013112959A8 (en) Antifibrotic compounds and uses thereof
WO2011141488A3 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
MX2014010433A (en) Novel crystalline form of sitagliptin sulfate.
WO2012116196A3 (en) Substituted lactosyl compounds and use thereof for cellular imaging and therapy
MX2014003701A (en) Compounds for the treatment and prophylaxis of respiratory syncytial virus disease.
WO2012103282A3 (en) Methods and compositions for treating alzheimer's disease
WO2013111013A8 (en) Methods for treating alzheimer's disease by administering certain synthetic compounds
WO2013081420A3 (en) Phenoxypropanol derivative and pharmaceutical composition containing same
WO2013038200A3 (en) Neurodevelopmental disorders
WO2011114071A3 (en) Synthetic cyclopeptide, preparation process and uses

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 14374573

Country of ref document: US

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13740537

Country of ref document: EP

Kind code of ref document: A2